Antidepressants and the placebo effect

Zeitschrift fur Psychologie / Journal of Psychology

Volumn 222, Issue 3, 2014, Pages 128-134

  Kirsch, Irving ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Depression; Effectiveness; Placebo; Serotonin

Indexed keywords

EID: 84906965628     PISSN: 21908370     EISSN: 21512604     Source Type: Journal    
DOI: 10.1027/2151-2604/a000176     Document Type: Review

References (37)

1. Andrews, P. W., Thomson, J. A., Amstadter, A., & Neale, M. C. (2012). Primum non nocere: An evolutionary analysis of whether antidepressants do more harm than good. [Review]. Frontiers in Psychology, 3, 117. doi: 10.3389/ fpsyg.2012.00117
2. Babyak, M. A., Blumenthal, J. A., Herman, S., Khatri, P., Doraiswamy, P. M., Moore, K. A., ...Krishnan, K. R. (2000). Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months. Psychosomatic Medicine, 62, 633-638.
3. Beutler, L. E. (1998). Prozac and placebo: There's a pony in there somewhere. Prevention & Treatment, 1, 3c. doi: 10.1037/1522-3736.1.2.13c
4. Dobson, K. S., Hollon, S. D., Dimidjian, S., Schmaling, K. B., Kohlenberg, R. J., Gallop, R. J., ...Jacobson, N. S. (2008). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. Journal of Consulting and Clinical Psychology, 76, 468-477. doi: 10.1037/0022-006X.76.3.468
5. Domar, A. D., Moragianni, V. A., Ryley, D. A., & Urato, A. C. (2013). The risks of selective serotonin reuptake inhibitor use in infertile women: A review of the impact on fertility, pregnancy, neonatal health and beyond. Human Reproduction, 28, 160-171. doi: 10.1093/humrep/des383
6. Fountoulakis, K. N., & Mc¸ller, H. J. (2011). Efficacy of antidepressants: A re-analysis and re-interpretation of the Kirsch data. International Journal of Neuro-Psychopharmacology, 14, 405.
7. Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. Journal of the American Medical Association, 303, 47-53. doi: 10.1001/jama. 2009.1943
8. Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Lohr, K. N. (2011). Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder. Annals of Internal Medicine, 155, 772-785. doi: 10.1059/0003-4819-155-11-201112060-00009
9. Hollon, S. D., DeRubeis, R. J., Shelton, R. C., & Weiss, B. (2002). The emperor's new drugs: Effect size and moderation effects. Prevention and Treatment, 5, 28. doi: 10.1037/ 1522-3736.5.1.528c
10. Hunter, A. M., Leuchter, A. F., Morgan, M. L., & Cook, I. A. (2006). Changes in brain function (quantitative eeg cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. American Journal of Psychiatry, 163, 1426-1432.
11. Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., ...Lembo, A. J. (2010). Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS One, 5, e15591. doi: 10.1371/journal.pone.0015591
12. Kelley, J. M., Kaptchuk, T. J., Cusin, C., Lipkin, S., & Fava, M. (2012). Open-label placebo for major depressive disorder: A pilot randomized controlled trial. Psychotherapy and Psychosomatics, 81, 312-314.
13. Khan, A., Faucett, J., Lichtenberg, P., Kirsch, I., & Brown, W. A. (2012). A systematic review of comparative efficacy of treatments and controls for depression. PLoS One, 7, e41778. doi: 10.1371/journal.pone.0041778
14. Khin, N. A., Chen, Y. F., Yang, Y., Yang, P., & Laughren, T. P. (2011). Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. Journal of Clinical Psychiatry, 72, 464-472. doi: 10.4088/ JCP.10m06191
15. Kirsch, I. (1998). Reducing noise and hearing placebo more clearly. Prevention & Treatment, 1, 7r. doi: 10.1037/1522-3736.1.1.17r
16. Kirsch, I. (2009). The emperor's new drugs: Exploding the antidepressant myth. London, UK: Bodley Head.
17. Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5, e45. doi: 10.1371/journal.pmed.0050045
18. Kirsch, I., Moore, T. J., Scoboria, A., & Nicholls, S. S. (2002). The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention and Treatment, 5, 23. doi: 10.1037/1522-3736.5.1.523a
19. Kirsch, I., & Sapirstein, G. (1998). Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention and Treatment, 1, 2a. doi: 10.1037/1522-3736.1.1.12a
20. Klein, D. F. (1998). Listening to meta-analysis but hearing bias. Prevention & Treatment, 1, 6c. doi: 10.1037/1522-3736.1.1.16c
21. Leber, P. (1998). Approvable action on Forrest Laboratories, Inc. NDA 20-822 Celexa (citalopram HBr) for the management of depression. In Memoradum to the Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research May 4. Washington, DC: FDA.
22. Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003). Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. British Medical Journal, 326, 1171-1173.
23. NICE. (2004). Depression: Management of depression in primary and secondary care [Clinical practice guideline 23] Retrieved from www.nice.org.uk/page.aspx?o = 235213. London, UK: National Institute for Health and Care Excellence.
24. Quitkin, F. M., McGrath, P. J., Stewart, J. W., Ocepek-Welikson, K., Taylor, B. P., Nunes, E., ...Klein, D. F. (1998). Placebo run-in period in studies of depressive disorders: Clinical, heuristic and research implications. British Journal of Psychiatry, 173, 242-248.
25. Rabkin, J. G., Markowitz, J. S., Stewart, J. W., McGrath, P. J., Harrison, W., Quitkin, F. M., & Klein, D. F. (1986). How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Research, 19, 75-86.
26. Raz, A., Campbell, N., Guindi, D., Holcroft, C., De´ry, C., & Cukier, O. (2011). Placebos in clinical practice: A Pan-Canadian Review of attitudes and patterns of use between academic psychiatrists and non-psychiatrists. Canadian Journal of Psychiatry, 56, 198-208.
27. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., ...Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163, 1905-1917.
28. Rutherford, B. R., Sneed, J. R., & Roose, S. P. (2009). Does study design influence outcome? Psychotherapy and Psychosomatics, 78, 172-181.
29. Serretti, A., & Chiesa, A. (2009). Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. Journal of Clinical Psychopharmacology, 29, 259-266.
30. Simon, G. E., & VonKorff, M. (1997). Prevalence, burden, and treatment of insomnia in primary care. American Journal of Psychiatry, 154, 1417-1423.
31. Teasdale, J. D. (1985). Psychological treatments for depression: How do they work? Behaviour Research and Therapy, 23, 157-165.
32. Thase, M. E. (2002). Antidepressant effects: The suit may be small, but the fabric is real. Prevention & Treatment, 5, 32. doi: 10.1037/1522-3736.5.1.532c
33. Tilburt, J. C., Emanuel, E. J., Kaptchuk, T. J., Curlin, F. A., & Miller, F. G. (2008). Prescribing "placebo treatments": Results of national survey of US internists and rheumatologists. British Medical Journal, 337, 1097-1100. doi: 10.1136/bmj.a1938
34. Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358, 252-260.
35. Wagstaff, A. J., Ormrod, D., & Spencer, C. M. (2001). Tianeptine: A review of its use in depressive disorders. CNS Drugs, 15, 231-259.
36. Wiegand, M. H. (2008). Antidepressants for the treatment of insomnia: A suitable approach? Drugs, 68, 2411-2417.
37. Zimmerman, M., Chelminski, I., & Posternak, M. A. (2005). Generalizability of antidepressant efficacy trials: Differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. American Journal of Psychiatry, 162, 1370-1372. doi: 10.1176/appi.ajp. 162.7.1370